RGNX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
108.0M
+1589.6%
6.4M
-78.9%
30.3M
+2.0%
29.7M
+39.2%
21.4M
Cost of Revenue
1.0M
-90.6%
11.1M
+86.8%
5.9M
+3.5%
5.7M
+9.9%
5.2M
Gross Profit
107.0M
+2385.3%
-4681000
-119.2%
24.4M
+1.7%
24.0M
+48.7%
16.1M
Operating Expenses
77.7M
-1.2%
78.7M
-4.1%
82.0M
+7.4%
76.4M
-3.8%
79.4M
R&D
56.1M
-2.2%
57.3M
-3.8%
59.6M
+6.3%
56.1M
-5.7%
59.5M
SG&A
21.6M
+1.5%
21.3M
-4.8%
22.4M
+10.5%
20.3M
+1.9%
19.9M
Operating Income
29.3M
+135.1%
-83362000
-44.6%
-57636000
-10.0%
-52411000
+17.2%
-63278000
EBITDA
33.0M
+141.5%
-79505000
-47.9%
-53767000
-10.8%
-48525000
+18.3%
-59373000
Net Income
22.7M
+125.2%
-90051000
-34.1%
-67149000
-8.4%
-61941000
+12.6%
-70871000
EPS (Basic)
$0.43
+125.0%
$-1.72
-32.3%
$-1.30
-8.3%
$-1.20
+13.0%
$-1.38
EPS (Diluted)
$0.43
+125.0%
$-1.72
-32.3%
$-1.30
-8.3%
$-1.20
+13.0%
$-1.38
Shares (Diluted)
53.0M
+1.1%
52.4M
+1.4%
51.7M
-0.0%
51.7M
+0.4%
51.5M
REGENXBIO (RGNX) โ€” Financials